|
Malignant Neoplasms
|
0.060 |
GeneticVariation
|
group |
BEFREE |
The correlation of genetic polymorphisms of CYP2W1 and cancer risk was uncertain.5.
|
27690753 |
2017 |
|
Colorectal Carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
CYP2W1 variant alleles in Caucasians and association of the CYP2W1 G541A (Ala181Thr) polymorphism with increased colorectal cancer risk.
|
20602611 |
2010 |
|
Colorectal Carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
These epidemiological data obtained from a large population of CRC patients and controls cannot confirm the previously suggested decreased risk for CRC among carriers of CYP2W1*2.
|
24088132 |
2013 |
|
Primary malignant neoplasm
|
0.060 |
GeneticVariation
|
group |
BEFREE |
The correlation of genetic polymorphisms of CYP2W1 and cancer risk was uncertain.5.
|
27690753 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
CYP2W1 variant alleles in Caucasians and association of the CYP2W1 G541A (Ala181Thr) polymorphism with increased colorectal cancer risk.
|
20602611 |
2010 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
CYP2W1 polymorphism: functional aspects and relation to risk for colorectal cancer.
|
24088132 |
2013 |
|
Malignant neoplasm of breast
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In this report, and for the first time in the literature, we analyzed the rs3735684 (7021 G>A), rs11553651 (15016 G>T) and rs56195291 (60020 C>G) polymorphisms in the CYP2W1, 4F11 and 8A1 genes in patients with BCa and in healthy Mexican women to identify a potential association between these polymorphisms and BCa risk.
|
22631658 |
2012 |
|
Breast Carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In this report, and for the first time in the literature, we analyzed the rs3735684 (7021 G>A), rs11553651 (15016 G>T) and rs56195291 (60020 C>G) polymorphisms in the CYP2W1, 4F11 and 8A1 genes in patients with BCa and in healthy Mexican women to identify a potential association between these polymorphisms and BCa risk.
|
22631658 |
2012 |
|
Hyperglycemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Tobaco, obesity and hyperglycemia significantly increased the risk of BCa in the patients carrying variant genotypes of CYP2W1 (P<0.05).
|
22631658 |
2012 |
|
Obesity
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Tobaco, obesity and hyperglycemia significantly increased the risk of BCa in the patients carrying variant genotypes of CYP2W1 (P<0.05).
|
22631658 |
2012 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Cytochrome P450 2W1 (CYP2W1) is a colon tumor-specific enzyme, suggested as a potential target for cancer therapy.
|
26787547 |
2016 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
It is concluded that CYP2W1 represents a tumor-specific P450 isoform with potential importance as a drug target in cancer therapy.
|
16426568 |
2006 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
The selective expression in some forms of cancers and the low expression in normal tissues render CYP2W1 as a possible drug target during cancer therapy.
|
17150034 |
2007 |
|
Colonic Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Indolines constitute high affinity exogenous compounds and specific chloromethylindolines have been shown to be activated by CYP2W1 into cytotoxic products in vitro and also in vivo, inhibiting the growth of human colon tumors in a mouse xenograft model.
|
27257736 |
2016 |
|
Colonic Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Cytochrome P450 2W1 (CYP2W1) is a colon tumor-specific enzyme, suggested as a potential target for cancer therapy.
|
26787547 |
2016 |
|
Colorectal Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Colorectal cancer-specific cytochrome P450 2W1: intracellular localization, glycosylation, and catalytic activity.
|
20805301 |
2010 |
|
Colorectal Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
CYP2W1 expression level was suggested to serve as an independent prognostic biomarker in colorectal cancer and hepatocellular carcinoma.
|
27690753 |
2017 |
|
Colorectal Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
The CRC specific localization of CYP2W1 and its effective prodrug activation makes it a very promising target for future development of cancer therapeutics.
|
27257736 |
2016 |
|
Colorectal Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
CYP2W1 has been proposed as an attractive target for colorectal cancer (CRC) therapy by exploiting its ability to activate duocarmycin prodrugs to cytotoxic metabolites.
|
25844926 |
2015 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
The imatinib mediated induction of CYP2W1 suggests an adjuvant therapy to treatment with duocarmycins that thus would involve induction of tumor CYP2W1 levels followed by the CYP2W1 activated duocarmycin prodrugs.
|
25844926 |
2015 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
However, the role of CYP2W1 in the endogenous and tumor localized metabolism of retinol derivatives has yet to be clarified.
|
27257736 |
2016 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
It is concluded that CYP2W1 represents a tumor-specific P450 isoform with potential importance as a drug target in cancer therapy.
|
16426568 |
2006 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
The selective expression in some forms of cancers and the low expression in normal tissues render CYP2W1 as a possible drug target during cancer therapy.
|
17150034 |
2007 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Cytochrome P450 2W1 (CYP2W1) is a colon tumor-specific enzyme, suggested as a potential target for cancer therapy.
|
26787547 |
2016 |
|
Malignant tumor of colon
|
0.050 |
Biomarker
|
disease |
BEFREE |
Membrane topology and search for potential redox partners of colon cancer-specific cytochrome P450 2W1.
|
26787547 |
2016 |